Matches in Nanopublications for { ?s ?p "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_assertion description "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance.
- assertion description "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_assertion description "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP416375.RADSvtEekEGYKUKNiVb8mASMElJW49zNXpCkKlcJv98cA130_provenance.
- NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_assertion description "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_provenance.
- NP949382.RA9GqzJvcefbvkkD9eqAkSLhRtH-Hy038cVLHDeE389l4130_assertion description "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP949382.RA9GqzJvcefbvkkD9eqAkSLhRtH-Hy038cVLHDeE389l4130_provenance.
- NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_assertion description "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_provenance.